MCID: ACT020
MIFTS: 45

Acute T Cell Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acute T Cell Leukemia

MalaCards integrated aliases for Acute T Cell Leukemia:

Name: Acute T Cell Leukemia 12 14
T-Cell Acute Lymphoblastic Leukemia 12 29
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 69
Precursor T-Cell Lymphoblastic Lymphoma 69
Precursor T Lymphoblastic Leukemia 12
Leukemia, Acute T-Cell 13

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
ICD10 33 C91.5 C91.50
MeSH 42 D015459
NCIt 47 C3184
UMLS 69 C0023493

Summaries for Acute T Cell Leukemia

MalaCards based summary : Acute T Cell Leukemia, also known as t-cell acute lymphoblastic leukemia, is related to precursor t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with Acute T Cell Leukemia is BCL10 (B-Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Pathways in cancer and p53 Signaling. The drugs Arranon and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and b cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for Acute T Cell Leukemia

Graphical network of the top 20 diseases related to Acute T Cell Leukemia:



Diseases related to Acute T Cell Leukemia

Symptoms & Phenotypes for Acute T Cell Leukemia

MGI Mouse Phenotypes related to Acute T Cell Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 BAX BCL10 CASP8 CD151 CXCL12 FASLG
2 hematopoietic system MP:0005397 9.97 LMO2 ZFP36L2 BAX BCL10 CASP8 CD151
3 endocrine/exocrine gland MP:0005379 9.91 BAX BCL10 CASP8 CD7 FASLG HSD17B1
4 immune system MP:0005387 9.91 BAX BCL10 CASP8 CD151 CD7 CXCL12
5 mortality/aging MP:0010768 9.85 CASP8 CD151 CXCL12 FASLG LMO1 LMO2
6 neoplasm MP:0002006 9.43 BAX CASP8 CD151 FASLG LMO2 ZFP36L2
7 renal/urinary system MP:0005367 9.1 BAX CASP8 CD151 FASLG LMO2 ZFP36L2

Drugs & Therapeutics for Acute T Cell Leukemia

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 46 NELARABINE GlaxoSmithKline October 2005

Drugs for Acute T Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
5
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
8
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
9
Epirubicin Approved Phase 4 56420-45-2 41867
10
Gemcitabine Approved Phase 4 95058-81-4 60750
11
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 2180-92-9, 38396-39-3 2474
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13 Antilymphocyte Serum Phase 4,Phase 3,Phase 1,Phase 2
14 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
24 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
25 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1
31 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
33 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Anesthetics, Local Phase 4,Phase 2,Phase 1
36 Calamus Nutraceutical Phase 4
37
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
38
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
39
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
40
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
41
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
42
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
43
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
44
Vindesine Approved Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
45
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
46
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 1 2353-33-5 451668
47
Fludarabine Approved Phase 3,Phase 1,Phase 2 21679-14-1, 75607-67-9 30751
48
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
49
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
50
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 449)

id Name Status NCT ID Phase Drugs
1 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Unknown status NCT02290132 Phase 4 Rabbit Anti-human Thymocyte Globulin (ATG)
2 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
3 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
4 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
5 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Not yet recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
6 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
7 Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00707083 Phase 3 dexamethasone;mercaptopurine;methotrexate;vincristine sulfate
8 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
9 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
10 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
11 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
12 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
13 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
14 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
15 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
16 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
17 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
18 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
19 Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
20 Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
21 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
22 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
23 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
24 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
25 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
26 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
27 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
28 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
29 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
30 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
31 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
32 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin
33 A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Recruiting NCT02716233 Phase 3 pegaspargase 1250 IU/m2 x 2;pegaspargase 2500 IU/m2 x 1
34 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Mesna;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
35 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
36 TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Recruiting NCT00914628 Phase 3
37 Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device Recruiting NCT02600208 Phase 2, Phase 3
38 CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Recruiting NCT02942173 Phase 2, Phase 3
39 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL Recruiting NCT02393859 Phase 3 Blinatumomab;Conventional Consolidation Chemotherapy
40 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
41 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
42 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting NCT00557193 Phase 3 vincristine sulfate;daunorubicin hydrochloride;cyclophosphamide;pegaspargase;asparaginase;prednisone;methylprednisolone;dexamethasone;cytarabine;methotrexate;therapeutic hydrocortisone;leucovorin calcium;etoposide;mercaptopurine;lestaurtinib
43 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Active, not recruiting NCT01295710 Phase 3
44 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Active, not recruiting NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
45 Treatment of Acute Lymphoblastic Leukemia in Children Active, not recruiting NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
46 Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00703820 Phase 3 Cytarabine;Daunorubicin;Etoposide;Clofarabine
47 Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer Not yet recruiting NCT02999854 Phase 3 Cyclophosphamide
48 Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Terminated NCT00003056 Phase 3 cyclosporine;cyclosporine and methotrexate
49 To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning Withdrawn NCT00226512 Phase 3 Campath-1H /ATG
50 T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) Unknown status NCT00242515 Phase 1, Phase 2

Search NIH Clinical Center for Acute T Cell Leukemia

Genetic Tests for Acute T Cell Leukemia

Genetic tests related to Acute T Cell Leukemia:

id Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for Acute T Cell Leukemia

MalaCards organs/tissues related to Acute T Cell Leukemia:

39
T Cells, Myeloid, B Cells, Bone, Bone Marrow, Thyroid, Nk Cells

Publications for Acute T Cell Leukemia

Articles related to Acute T Cell Leukemia:

(show all 28)
id Title Authors Year
1
Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia inA vivo in a mouse xenogtraft model. ( 27998762 )
2016
2
Articulatin-D induces apoptosis via activation of caspase-8 in acute T-cell leukemia cell line. ( 27868169 )
2016
3
Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. ( 27756877 )
2016
4
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. ( 26058075 )
2015
5
Mir-55 inhibition can reduce cell proliferation and induce apoptosis in Jurkat (Acute T cell Leukemia) cell line. ( 25598954 )
2014
6
Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: Prooxidative potential of hydroxylated resveratrol analogs. ( 24398169 )
2014
7
Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells. ( 24394624 )
2014
8
Conversion of estrone to 17 beta-estradiol in Jurkat acute T cell leukemia Hut-78 T- and Raji B lymphoma cell lines in vitro. ( 23540283 )
2013
9
Combined treatment with fenretinide and indomethacin induces AIF-mediated, non-classical cell death in human acute T-cell leukemia Jurkat cells. ( 22387538 )
2012
10
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. ( 20008304 )
2010
11
Complete regression of massive cardiac involvement associated with acute T cell leukemia following chemotheraphy. ( 17320483 )
2008
12
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. ( 16332967 )
2006
13
Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. ( 16502262 )
2006
14
Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation. ( 16266918 )
2005
15
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). ( 15774621 )
2005
16
Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. ( 14715100 )
2003
17
A novel post-transcriptional splicing form of the acute T cell leukemia proto-oncogene Lmo2. ( 18763096 )
2001
18
Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia. ( 8545129 )
1995
19
Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. ( 1371092 )
1992
20
Acute T-cell leukemia/lymphoma mimicking Hodgkin's disease with secondary HTLV I seroconversion. ( 2208004 )
1990
21
A case of CD3+, CD4-, CD8-, WT31- acute T-cell leukemia. ( 2787596 )
1989
22
Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. ( 2546621 )
1989
23
Constitutive expression and abnormal glycosylation of transferrin receptor in acute T-cell leukemia. ( 2582441 )
1989
24
Cyclosporine A and acute T cell leukemia in the rat. ( 3164536 )
1988
25
T-lymphoblasts with erythropoietic helper function in acute T-cell leukemia. ( 2978965 )
1986
26
Childhood primary cutaneous non-T/non-B lymphoma followed by acute T-cell leukemia. ( 3486034 )
1986
27
t(11;19)(q23;p11) in a child with acute T-cell leukemia. ( 3855377 )
1985
28
Human serum thymic factor in detecting acute T cell leukemia. ( 311636 )
1978

Variations for Acute T Cell Leukemia

ClinVar genetic disease variations for Acute T Cell Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511
2 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
3 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh37 Chromosome 19, 49458972: 49458978

Copy number variations for Acute T Cell Leukemia from CNVD:

7 (show top 50) (show all 91)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for Acute T Cell Leukemia

Search GEO for disease gene expression data for Acute T Cell Leukemia.

Pathways for Acute T Cell Leukemia

GO Terms for Acute T Cell Leukemia

Biological processes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.63 BCL10 CASP8 FASLG
2 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.58 BAX CASP8 FASLG
3 apoptotic signaling pathway GO:0097190 9.54 BAX CASP8 FASLG
4 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.51 CASP8 FASLG
5 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.49 BAX FASLG
6 homeostasis of number of cells within a tissue GO:0048873 9.48 BAX CD7
7 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.43 CASP8 FASLG
8 extrinsic apoptotic signaling pathway GO:0097191 9.33 BAX CASP8 FASLG
9 B cell apoptotic process GO:0001783 9.32 BAX BCL10
10 T cell apoptotic process GO:0070231 9.26 BCL10 FASLG
11 retinal cell programmed cell death GO:0046666 8.96 BAX FASLG
12 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 8.8 BAX CASP8 FASLG

Molecular functions related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.96 CASP8 FASLG
2 death receptor binding GO:0005123 8.62 CASP8 FASLG

Sources for Acute T Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....